Clinical Trial Update: Interferon Signature in Anti-CTLA-4 and Anti-PD-1/PD-L1-Treated Cancer Patients Compared With Systemic Autoimmune Disease Patients

View source ↗

Summary

A recruiting clinical trial examining interferon signature differences between cancer patients treated with anti-CTLA-4 or anti-PD-1/PD-L1 therapies and systemi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Inflammatory Myopathies
• Malignant Solid Tumors
• Sjögren Syndrome
• Systemic Lupus Erythematosus
• Systemic Sclerosis

Drugs mentioned

• Atezolizumab (atezolizumab)
• Pembrolizumab (pembrolizumab)
• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: Hospital Universitario Araba | Conditions: Immune-Related Adverse Events, Lupus Erythematosus, Systemic | Status: RECRUITING